CD274 and neoplasm: The most crucial issue in anti-tumor treatment is fixing the therapeutic targets, and increasing studies report that immune checkpoint blockade (ICB) can stimulate the immune system using PD-L1 antibodies, while tumor cells often resist anti-PD-L1 therapy via immune evasion.